RECURSION PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$537.64 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$537.64M.
- RECURSION PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$422.85M.
- RECURSION PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$314.37M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$537.64M 10-K · filed 2026-02-25 |
| 2024-12-31 | -$422.85M 10-K · filed 2026-02-25 |
| 2023-12-31 | -$314.37M 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |